HK1140949A1 - Liquid formulations of salts of 4-[2-(4-methylphenylsulfanyl) phenyl]piperidine 4-[2-(4-)-] - Google Patents

Liquid formulations of salts of 4-[2-(4-methylphenylsulfanyl) phenyl]piperidine 4-[2-(4-)-]

Info

Publication number
HK1140949A1
HK1140949A1 HK10107411.4A HK10107411A HK1140949A1 HK 1140949 A1 HK1140949 A1 HK 1140949A1 HK 10107411 A HK10107411 A HK 10107411A HK 1140949 A1 HK1140949 A1 HK 1140949A1
Authority
HK
Hong Kong
Prior art keywords
methylphenylsulfanyl
piperidine
phenyl
salts
liquid formulations
Prior art date
Application number
HK10107411.4A
Other languages
English (en)
Inventor
Gudrun Lasskogen
Tine Bryan Stensboel
De Diego Heidi Lopez
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/DK2007/050076 external-priority patent/WO2007144006A1/en
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of HK1140949A1 publication Critical patent/HK1140949A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
HK10107411.4A 2007-03-20 2010-08-03 Liquid formulations of salts of 4-[2-(4-methylphenylsulfanyl) phenyl]piperidine 4-[2-(4-)-] HK1140949A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200700423 2007-03-20
PCT/DK2007/050076 WO2007144006A1 (en) 2006-06-16 2007-06-15 Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
DKPA200701790 2007-12-14
PCT/DK2008/050062 WO2008113358A1 (en) 2007-03-20 2008-03-14 Liquid formulations of salts of 4-[2-(4-methylphenylsulfanyl)phenyl]piperidine

Publications (1)

Publication Number Publication Date
HK1140949A1 true HK1140949A1 (en) 2010-10-29

Family

ID=39327217

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10107411.4A HK1140949A1 (en) 2007-03-20 2010-08-03 Liquid formulations of salts of 4-[2-(4-methylphenylsulfanyl) phenyl]piperidine 4-[2-(4-)-]

Country Status (27)

Country Link
US (1) US20100105730A1 (xx)
EP (2) EP2388004A1 (xx)
JP (1) JP5301474B2 (xx)
KR (1) KR20090130000A (xx)
AR (1) AR065796A1 (xx)
AT (1) ATE526966T1 (xx)
AU (1) AU2008228637B2 (xx)
BR (1) BRPI0808820A2 (xx)
CA (1) CA2684592C (xx)
CL (1) CL2008000797A1 (xx)
CO (1) CO6220958A2 (xx)
CY (1) CY1112285T1 (xx)
DK (1) DK2129377T3 (xx)
EA (1) EA019695B1 (xx)
ES (1) ES2373275T3 (xx)
HK (1) HK1140949A1 (xx)
HR (1) HRP20110844T1 (xx)
IL (1) IL200959A (xx)
MX (1) MX2009009388A (xx)
MY (1) MY148695A (xx)
NZ (1) NZ579717A (xx)
PL (1) PL2129377T3 (xx)
PT (1) PT2129377E (xx)
RS (1) RS52050B (xx)
SI (1) SI2129377T1 (xx)
TW (1) TWI405588B (xx)
WO (1) WO2008113358A1 (xx)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008151632A1 (en) * 2007-06-15 2008-12-18 H.Lundbeck A/S 4- [2- (4-methylphenylsulfanyl) phenyl] piperidine for the treatment of irritable bowel syndrome (ibs)
TWI432194B (zh) 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
EA021122B1 (ru) * 2009-04-24 2015-04-30 Х. Лундбекк А/С Жидкие составы солей 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазина
SG185081A1 (en) 2010-04-30 2012-12-28 Takeda Pharmaceutical Enteric tablet
KR20130060220A (ko) 2010-04-30 2013-06-07 다케다 야쿠힌 고교 가부시키가이샤 장용성 정제

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10163326A1 (de) * 2001-07-30 2003-02-27 Disetronic Licensing Ag Verabreichungsgerät mit Dosiervorrichtung
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
JP4405802B2 (ja) * 2001-10-16 2010-01-27 メディカル・インスティル・テクノロジーズ・インコーポレイテッド 計量された量の物質を供給するための、密閉チャンバ及び一方向弁を備えたディスペンサ
DE10202367A1 (de) 2002-01-23 2003-09-25 Duerr Dental Gmbh Co Kg Applikator für flüssige oder viskose Substanzen
SI1626720T1 (sl) * 2003-04-04 2008-12-31 Lundbeck & Co As H Derivati 4-(2-fenilsulfanil-fenil)-piperidina kotzaviralci ponovnega vnosa serotonina
PL2044020T3 (pl) * 2006-06-16 2011-09-30 H Lundbeck As Krystaliczne postaci 4-[2-(4-metylofenylosulfanylo)-fenylo]piperydyny z równoczesnym hamowaniem wychwytu zwrotnego serotoniny i norepinefryny do leczenia bólu neuropatycznego
KR101367136B1 (ko) * 2007-07-27 2014-02-25 삼성디스플레이 주식회사 유기 발광 표시 장치 및 이의 제조 방법

Also Published As

Publication number Publication date
EA200970869A1 (ru) 2010-02-26
CL2008000797A1 (es) 2008-09-26
AU2008228637A1 (en) 2008-09-25
SI2129377T1 (sl) 2012-01-31
EP2129377B1 (en) 2011-10-05
BRPI0808820A2 (pt) 2014-08-19
IL200959A (en) 2011-12-29
NZ579717A (en) 2012-06-29
JP5301474B2 (ja) 2013-09-25
US20100105730A1 (en) 2010-04-29
AR065796A1 (es) 2009-07-01
CO6220958A2 (es) 2010-11-19
CY1112285T1 (el) 2015-12-09
JP2010521500A (ja) 2010-06-24
IL200959A0 (en) 2010-05-17
EP2388004A1 (en) 2011-11-23
PT2129377E (pt) 2011-12-23
CA2684592A1 (en) 2008-09-25
DK2129377T3 (da) 2012-01-02
MX2009009388A (es) 2009-11-25
EA019695B1 (ru) 2014-05-30
CA2684592C (en) 2013-11-12
WO2008113358A1 (en) 2008-09-25
TWI405588B (zh) 2013-08-21
ES2373275T3 (es) 2012-02-01
ATE526966T1 (de) 2011-10-15
HRP20110844T1 (hr) 2011-12-31
AU2008228637B2 (en) 2013-03-21
EP2129377A1 (en) 2009-12-09
TW200902083A (en) 2009-01-16
KR20090130000A (ko) 2009-12-17
PL2129377T3 (pl) 2012-02-29
MY148695A (en) 2013-05-31
RS52050B (en) 2012-04-30

Similar Documents

Publication Publication Date Title
FR18C1020I2 (fr) Sels pharmaceutiquement acceptables de 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide
ZA201107731B (en) Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
ME02307B (me) Kristalni (r)-(e)-2-(4-(2-(5-(1-(3,5-diklorpiridin-4-il)etoksi)-1h-indazol- 3-il)vinil)-1h-pirazol-1-il)etanol i njegova upotreba kao inhibitora fgfr
BRPI0921596A2 (pt) Compostos de 4-[2-(2-fluorofenoximetil) fenil] piperidina
IL197420A0 (en) Polymorphic form of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-
SMT201600304B (it) Sale cloridrato di 4-[2-[[5-metil-1-(2- naftalenil]-1h-pirazol-3- il]ossi]etil]morfolina
ZA201003909B (en) Crystalline 2-(4-cyclopropanesulphonyl-phenyl)-n-pyrazin-2-yl-3-(tetrahydopyran-4-yl)-propionamide
PT2167085E (pt) Novas utilizações terapêuticas de 4-[2-(4- metilfenilsulfanil)fenil]piperidina
IL217914A0 (en) New compositions of 1-[2-(2'4-dimethyl-phenylsulfanyl)-phenyl]piperazine
HK1140949A1 (en) Liquid formulations of salts of 4-[2-(4-methylphenylsulfanyl) phenyl]piperidine 4-[2-(4-)-]
BRPI0816221A8 (pt) forma cristalina 1 da 2-((r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida
ZA201003031B (en) 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid-465
IL196773A0 (en) Stable solid elsamitrucin salts suitable for pharmaceutical formulations
EP2225255A4 (en) CRYSTALLINE FORMS OF 2- [2- (4-CHLOROPHENYL) ETHOXY] ADENOSINE

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20160314